Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Sallman DA, Garcia-Manero G, Daver N, et al. (2026). "Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-25-00617